CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 231 enrolled
Drug / intervention
Impedance cardiographydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06277388
NCT06277388N/AActive

Hemodynamic Changes and Prognostic Analysis of Patients With Locally Advanced Non-small Cell Lung Cancer During Combined Chemoradiotherapy and Immunotherapy: An Observational Study Based on Dynamic Cardiac Output.

Sun Yat-sen University·observational·Posted Feb 26, 2024·Updated Mar 11, 2026

In Brief

An observational study evaluating Impedance cardiography for Non-small Cell Lung Cancer and Cardiac Toxicity. Active but no longer recruiting, targeting 231 participants across 1 site.

Detailed Summary

This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent combined concurrent chemoradiotherapy (CCRT) and immunotherapy. Additionally, It sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/AActiveOverdue
20222023202420252026
First PostedFeb 26, 2024
Enrollment StartJun 5, 2021
Primary CompletionSep 30, 2025
Study CompletionJun 30, 2026
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 2.3 years ago

Interventions

Impedance cardiographydevice

The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).